Healthcare Industry News: Xoft Axxent
News Release - May 3, 2013
iCAD’s Xoft Intraoperative Radiation Therapy System Featured at American Society of Breast Surgeons ConferenceNASHUA, N.H. & CHICAGO--(Healthcare Sales & Marketing Network)--Booth #303--iCAD, Inc. (ICAD), a leading provider of advanced imaging and radiation therapy technologies for the detection and treatment of cancer, today announced that the Company’s Xoft® Axxent® Electronic Brachytherapy System® for Intraoperative Radiation Therapy (IORT) will be a featured subject of several scientific and training sessions at the American Society of Breast Surgeons’ 14th Annual Meeting taking place this week at the Sheraton Chicago Hotel & Towers.
“We are pleased to have our Xoft System for the treatment of early-stage breast cancer so prominently featured before an audience of more than 1,000 of the world’s top breast surgeons at this premiere medical conference,” said Ken Ferry, President and CEO of iCAD. “The data presented further confirm the benefits of this therapy, and we look forward to new and continued opportunities to advance the treatment of breast cancer and improve the lives of patients.”
IORT data and innovations will be discussed in the following poster and educational session:
- “Intra-Operative Radiation Therapy for Treatment of Early Stage Breast Cancer: Short Term Results from a Single Institution Clinical Trial Using Electronic Brachytherapy with a Disposable Balloon Applicator”
The poster (#56) will be available for viewing as of 9:30 a.m. CT on Friday, May 3
Chicago Room 8-10, Level IV, Row J.
Barbara S. Schwartzberg, MD, Rose Medical Center, Denver, Colo., will review the results of a 51-patient trial of the Xoft® Axxent® Electronic Brachytherapy System®, finding no recurrences of breast cancer at an average of 14 months post-treatment from 6:00 p.m.-7:30 p.m. CT on Friday evening at the poster location.
- “Innovations and Advances in Breast Cancer Diagnosis and Treatment”
Friday, May 3, 4:00 p.m.-5:30 p.m. CT
Sheraton Chicago 4–7, Level IV
The IORT portion of the General Session discussion will be led by Darius S. Francescatti, MD, JD, FACS, Assistant Professor, Rush Presbyterian St. Luke’s Medical Center, Chicago, Ill.
About Xoft® Axxent® Electronic Brachytherapy System®
The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked for use anywhere in the body, including for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. A post-market study is underway to assess the safety and efficacy of Intraoperative Radiation Therapy with the Xoft System. Xoft, Inc. is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com.
About iCAD, Inc.
iCAD is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft System, offers radiation treatment for early-stage breast cancer that can be administered in the form of Intraoperative Radiation Therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer, endometrial and cervical cancers. For more information, call 877-iCADnow, or visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company’s ability to defend itself in litigation matters, the risks relating to the Company’s acquisition of Xoft including, the expected benefits of the acquisition may not be achieved in a timely manner, or at all; the Xoft business operations may not be successfully integrated with iCAD’s and iCAD may be unable to achieve the expected synergies, business and strategic objectives following the transaction, the risks of uncertainty of patent protection; the impact of supply and manufacturing constraints or difficulties; product market acceptance; possible technological obsolescence; increased competition; customer concentration; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.